BIOMAT Database Logo BIOMAT Database Logo

[Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association]. 1971

J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002262 Carboxy-Lyases Enzymes that catalyze the addition of a carboxyl group to a compound (carboxylases) or the removal of a carboxyl group from a compound (decarboxylases). EC 4.1.1. Carboxy-Lyase,Decarboxylase,Decarboxylases,Carboxy Lyase,Carboxy Lyases
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001593 Benzyl Compounds Benzene derivatives that contain a benzyl group with the general formula Phenyl-CH2-R. Compounds, Benzyl

Related Publications

J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
November 1972, Nederlands tijdschrift voor geneeskunde,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
June 1974, Wiener medizinische Wochenschrift (1946),
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
January 1972, Acta neurologica Scandinavica. Supplementum,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
January 1974, Acta neurologica latinoamericana,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
July 1970, Arzneimittel-Forschung,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
July 1970, Arzneimittel-Forschung,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
September 1969, Wiener klinische Wochenschrift,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
January 1972, Schweizerische medizinische Wochenschrift,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
December 1969, Deutsche Zeitschrift fur Nervenheilkunde,
J Wajsbort, and J A Hemli, and I Alfandary, and M Yahel, and J Siegfried
[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
April 1969, La Presse medicale,
Copied contents to your clipboard!